Showing 2791-2800 of 20410 results for "".
SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
https://reachmd.com/clinical-practice/cardiology/spirit-hf-does-spironolactone-improve-outcomes-in-hfpef-and-hfmref/57081/Review SPIRIT-HF findings evaluating spironolactone outcomes and safety in patients with HFpEF and HFmrEF.Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
https://reachmd.com/programs/cme/cracking-the-code-risk-stratification-guidelines-to-identify-high-risk-patients/57192/Explore individualized treatment intensification, molecular profiling, and adverse event management in metastatic hormone-sensitive prostate cancer.All Sides of the Joint: Integrated TGCT Care Across Specialties
https://reachmd.com/programs/cme/all-sides-of-the-joint-integrated-tgct-care-across-specialties/48912/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.To Implant or to Inject?
https://reachmd.com/programs/cme/To-Implant-or-to-Inject/54100/Explore the clinical promise of TKIs in managing exudative retinal diseases with insights on mechanisms, delivery, trials, and patient selection.Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
https://reachmd.com/programs/cme/early-diagnosis-its-pivotal-role-in-optimizing-outcomes-in-patients-with-endometriosis-psychosocial-and-physical-consequences/26288/A paradigm change that will impact your clinical practice is occurring in the diagnosis and medical management of endometriosis. Learn more!Anatomical Outcomes from the LIGHTSITE III Trial
https://reachmd.com/programs/cme/Anatomical-Outcomes-from-the-LIGHTSITE-III-Trial/35947/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effRisk Stratification and Patient Selection for Perioperative ICIs
https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Amesh Adalja, Infectious Disease Expert, Answers Your Latest COVID-19 Questions
https://reachmd.com/programs/public-health-call/amesh-adalja-infectious-disease-expert-answers-your-latest-covid-19-questions/11429/Is there any truth behind using hydroxychloroquine as a treatment? An infectious disease expert answers this and other FAQs.IBD Beyond Symptoms: What Community GIs Need to Know
https://reachmd.com/programs/cme/ibd-beyond-symptoms-what-community-gis-need-to-know/54127/Examine the biological mechanisms underlying IBD, including genetic, microbial, environmental, and immune pathways that inform therapeutic targets.Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
https://reachmd.com/programs/cme/choosing-the-path-forward-a-real-world-dialogue-on-perioperative-immunotherapy/57089/Explore perioperative immunotherapy in locally advanced HNSCC through patient–clinician dialogue, clinical evidence, and multidisciplinary care.